Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Molgramostim"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Трансплантология (Москва), Vol 0, Iss 3-4, Pp 18-22 (2018)
To study efficiency of molgramostim as an adjuvant in HBV vaccination we randomized 18 pts after OLT due to non-HBV causes. Nine pts received GM-CSF (150 mcg of sc 24 h before 1st dose of vaccine). Other 9 pts received only vaccine. Both groups of pt
Externí odkaz:
https://doaj.org/article/82d88b4dbaa14b3c9c3d056886e0f82c
Autor:
Yoshikazu Inoue, F. Bonella, Grant W. Waterer, Elisabeth Bendstrup, Bruce C. Trapnell, Ilaria Campo, C. Morgan, S. Jouneau
Publikováno v:
B16. ILD THERAPY II.
Autor:
Barbara Juliane Holzknecht, Sara Gamborg, Rasmus Alder, Jacob Rosenberg, Søren Roepstorff, Siv Fonnes, Christoffer Skov Olesen, Lars N. Jorgensen, Tilde Rasmussen, Line Schmidt, Joachim Hjalde Halmsted Olsen, Magnus Arpi
Publikováno v:
Frontiers in Surgery, Vol 7 (2020)
Frontiers in Surgery
Fonnes, S, Roepstorff, S, Holzknecht, B J, Olesen, C S, Olsen, J H H, Schmidt, L, Alder, R, Gamborg, S, Rasmussen, T, Arpi, M, Jørgensen, L N & Rosenberg, J 2020, ' Shorter Total Length of Stay After Intraperitoneal Fosfomycin, Metronidazole, and Molgramostim for Complicated Appendicitis : A Pivotal Quasi-Randomized Controlled Trial ', Frontiers in Surgery, vol. 7, 25 . https://doi.org/10.3389/fsurg.2020.00025
Frontiers in Surgery
Fonnes, S, Roepstorff, S, Holzknecht, B J, Olesen, C S, Olsen, J H H, Schmidt, L, Alder, R, Gamborg, S, Rasmussen, T, Arpi, M, Jørgensen, L N & Rosenberg, J 2020, ' Shorter Total Length of Stay After Intraperitoneal Fosfomycin, Metronidazole, and Molgramostim for Complicated Appendicitis : A Pivotal Quasi-Randomized Controlled Trial ', Frontiers in Surgery, vol. 7, 25 . https://doi.org/10.3389/fsurg.2020.00025
Background: We aimed to investigate the difference in the total length of hospital stay (LOS) after intraperitoneal vs. intravenous antibiotic treatment in patients with complicated appendicitis. Methods: We conducted a quasi-randomized prospective c
Autor:
Grant W. Waterer, Mikhail M. Ilkovich, Tomohisa Baba, Yoshikazu Inoue, Francesco Bonella, Cliff Morgan, Erdogan Cetinkaya, Taneli Jouhikainen, Etsuro Yamaguchi, Cecilia Ganslandt, Michael Kreuter, Impala Trial Investigators, Inge Tarnow, Ilaria Campo, Bruce C. Trapnell, Mordechai R. Kramer, Stéphane Jouneau, Marcel Veltkamp, Elisabeth Bendstrup, Spyros Papiris
Publikováno v:
New England Journal of Medicine
New England Journal of Medicine, 2020, 383 (17), pp.1635-1644. ⟨10.1056/NEJMoa1913590⟩
New England Journal of Medicine, Massachusetts Medical Society, 2020, 383 (17), pp.1635-1644. ⟨10.1056/NEJMoa1913590⟩
Trapnell, B C, Inoue, Y, Bonella, F, Morgan, C, Jouneau, S, Bendstrup, E, Campo, I, Papiris, S A, Yamaguchi, E, Cetinkaya, E, Ilkovich, M M, Kramer, M R, Veltkamp, M, Kreuter, M, Baba, T, Ganslandt, C, Tarnow, I, Waterer, G, Jouhikainen, T & IMPALA Trial Investigators 2020, ' Inhaled molgramostim therapy in autoimmune pulmonary alveolar proteinosis ', New England Journal of Medicine, vol. 383, no. 17, pp. 1635-1644 . https://doi.org/10.1056/NEJMoa1913590
N Engl J Med
New England Journal of Medicine, 2020, 383 (17), pp.1635-1644. ⟨10.1056/NEJMoa1913590⟩
New England Journal of Medicine, Massachusetts Medical Society, 2020, 383 (17), pp.1635-1644. ⟨10.1056/NEJMoa1913590⟩
Trapnell, B C, Inoue, Y, Bonella, F, Morgan, C, Jouneau, S, Bendstrup, E, Campo, I, Papiris, S A, Yamaguchi, E, Cetinkaya, E, Ilkovich, M M, Kramer, M R, Veltkamp, M, Kreuter, M, Baba, T, Ganslandt, C, Tarnow, I, Waterer, G, Jouhikainen, T & IMPALA Trial Investigators 2020, ' Inhaled molgramostim therapy in autoimmune pulmonary alveolar proteinosis ', New England Journal of Medicine, vol. 383, no. 17, pp. 1635-1644 . https://doi.org/10.1056/NEJMoa1913590
N Engl J Med
International audience; BACKGROUND: Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by progressive surfactant accumulation and hypoxemia. It is caused by disruption of granulocyte-macrophage colony-stimulating factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::826844342360d2379c4fc1e1f116ef8a
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85094220565
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85094220565
Publikováno v:
Respiratory Medicine Case Reports, Vol 23, Iss, Pp 167-169 (2018)
Gajewska, M E, Sritharan, S S, Santoni-Rugiu, E & Bendstrup, E M 2018, ' Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim) ', Respiratory medicine case reports, vol. 23, pp. 167-169 . https://doi.org/10.1016/j.rmcr.2018.02.005
Respiratory Medicine Case Reports
Gajewska, M E, Sritharan, S S, Santoni-Rugiu, E & Bendstrup, E M 2018, ' Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim) ', Respiratory medicine case reports, vol. 23, pp. 167-169 . https://doi.org/10.1016/j.rmcr.2018.02.005
Respiratory Medicine Case Reports
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare parenchymal lung disease characterized by accumulation of surfactant in the airways with high levels of granulocyte-macrophage colony stimulating factor (GM-CSF) antibodies in blood. Disease
Autor:
Michail Sideris, Dimosthenis Chrysikos, Theodoros Pittaras, Alexandros Nomikos, Apostolos Papalois, Maria Korontzi, John K Triantafillidis, Eleni Triantafyllidi, Calypso Barbatis
Publikováno v:
BioMed Research International
BioMed Research International, Vol 2019 (2019)
BioMed Research International, Vol 2019 (2019)
Background/Aim. Treatment with growth factors could be beneficial in both inflammatory bowel disease and experimental colitis. The aim of this study was to investigate the effect of Colony Stimulating Factor (CSF), and Recombinant Human (rHu) Granulo
Autor:
Cliff Morgan, Cecilia Ganslandt, Bruce C. Trapnell, Inge Tarnow, Grant W. Waterer, Taneli Jouhikainen
Publikováno v:
Clinical Problems.
IMPALA is an international Phase III, double-blind, placebo-controlled, randomized trial of inhaled recombinant human GM-CSF (molgramostim) in patients with moderate-severe autoimmune pulmonary alveolar proteinosis (APAP). As prior reports on APAP we
Autor:
Mette Vinge, Yoshikazu Inoue, Inge Tarnow, Francesco Bonella, Cliff Morgan, Cecilia Ganslandt, Kim Arvid Nielsen
Publikováno v:
1.5 Diffuse Parenchymal Lung Disease.
Background: APAP is a rare autoimmune disease with an estimated prevalence of 0.7 per 100,000. APAP is caused by accumulation of surfactant lipids and proteins in the alveoli, leading to progressive respiratory insufficiency. Spontaneous remissions a
Autor:
Ricardo Bizogne Souto, Renato Schutkoski, Diogo Paim Leal, Ana Cláudia Bergamo, Sérgio Luiz Dalmora
Publikováno v:
Biologicals. 39:211-216
The granulocyte-macrophage colony stimulating factor (GM-CSF) is a cytokine that regulates the proliferation and differentiation of hematopoietic cells and activates granulocytes and macrophages. A reversed-phase liquid chromatography (RP-LC) method